Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Matsue, Y., Suzuki, M., Nagahori, W., Yoshida, K., Onishi, Y., Satoh, Y., Ono, Y., Nishioka, T., Noda, M., Sugi, K., Torii, S., Tejima, T., Sakurada, H., Yamaguchi, S., Okishige, K., Fujii, H., & Takahashi, A. Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy, 28(1):73--77, February, 2014. doi abstract bibtex PURPOSE: Over half of all admitted acute decompensated heart failure (ADHF) patients have renal failure. Although diuretics represent the mainstay of treatment strategy even in this population, there are unmet needs for safer and more effective treatment. Tolvaptan is a vasopressin-2 receptor antagonist, and we hypothesized that adding tolvaptan to standard diuretic therapy would be more effective in ADHF patients with renal function impairment. METHODS: The Answering question on tolvaptan's efficacy for patients with acute decompensated heart failure and renal failure (AQUAMARINE) is a multicenter, randomized controlled clinical trial, which will enroll 220 patients from 17 hospitals in Japan. ADHF patients whose estimated glomerular filtration rate is above 15 and below 60 mL/min/1.72 m(2) will be randomly assigned within 6 h after admission to usual care with furosemide or tolvaptan add-on therapy. Primary endpoint is achieved urine output within 48 h. Secondary endpoints include dyspnea relief measured by 7-points Likert scale, incidence of worsening renal function, dose of furosemide used within 48 h, and changes of brain natriuretic peptide. CONCLUSION: This study is the first multicenter study in Japan to evaluate clinical effectiveness of tolvaptan add-on therapy in ADHF patients with renal failure. The results of this study address the treatment strategy of this high-risk population (UMIN Clinical Trial Registry Number: UMIN000007109).
@article{matsue_clinical_2014,
title = {Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the {AQUAMARINE} study},
volume = {28},
issn = {1573-7241},
shorttitle = {Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure},
doi = {10.1007/s10557-013-6491-8},
abstract = {PURPOSE: Over half of all admitted acute decompensated heart failure (ADHF) patients have renal failure. Although diuretics represent the mainstay of treatment strategy even in this population, there are unmet needs for safer and more effective treatment. Tolvaptan is a vasopressin-2 receptor antagonist, and we hypothesized that adding tolvaptan to standard diuretic therapy would be more effective in ADHF patients with renal function impairment.
METHODS: The Answering question on tolvaptan's efficacy for patients with acute decompensated heart failure and renal failure (AQUAMARINE) is a multicenter, randomized controlled clinical trial, which will enroll 220 patients from 17 hospitals in Japan. ADHF patients whose estimated glomerular filtration rate is above 15 and below 60 mL/min/1.72 m(2) will be randomly assigned within 6 h after admission to usual care with furosemide or tolvaptan add-on therapy. Primary endpoint is achieved urine output within 48 h. Secondary endpoints include dyspnea relief measured by 7-points Likert scale, incidence of worsening renal function, dose of furosemide used within 48 h, and changes of brain natriuretic peptide.
CONCLUSION: This study is the first multicenter study in Japan to evaluate clinical effectiveness of tolvaptan add-on therapy in ADHF patients with renal failure. The results of this study address the treatment strategy of this high-risk population (UMIN Clinical Trial Registry Number: UMIN000007109).},
language = {eng},
number = {1},
journal = {Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy},
author = {Matsue, Yuya and Suzuki, Makoto and Nagahori, Wataru and Yoshida, Kazuki and Onishi, Yuko and Satoh, Yasuhiro and Ono, Yuichi and Nishioka, Toshihiko and Noda, Makoto and Sugi, Kaoru and Torii, Sho and Tejima, Tamotsu and Sakurada, Harumizu and Yamaguchi, Satoshi and Okishige, Kaoru and Fujii, Hiroyuki and Takahashi, Atsushi},
month = feb,
year = {2014},
pmid = {24048511},
keywords = {Acute Disease, Antidiuretic Hormone Receptor Antagonists, Benzazepines, Diuretics, Drug Therapy, Combination, Furosemide, Glomerular Filtration Rate, Heart failure, Humans, Japan, Natriuretic Peptide, Brain, Prospective Studies, Renal Insufficiency, Research Design},
pages = {73--77}
}
Downloads: 0
{"_id":"zFqT4u65vvwZsysdp","bibbaseid":"matsue-suzuki-nagahori-yoshida-onishi-satoh-ono-nishioka-etal-clinicaleffectivenessoftolvaptaninpatientswithacutedecompensatedheartfailureandrenalfailuredesignandrationaleoftheaquamarinestudy-2014","downloads":0,"creationDate":"2017-09-21T01:29:59.576Z","title":"Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study","author_short":["Matsue, Y.","Suzuki, M.","Nagahori, W.","Yoshida, K.","Onishi, Y.","Satoh, Y.","Ono, Y.","Nishioka, T.","Noda, M.","Sugi, K.","Torii, S.","Tejima, T.","Sakurada, H.","Yamaguchi, S.","Okishige, K.","Fujii, H.","Takahashi, A."],"year":2014,"bibtype":"article","biburl":"https://api.zotero.org/users/465291/collections/IRKUUVWE/items?key=hwstUZQWv5PeUDo1dlxNM0pT&format=bibtex&limit=100","bibdata":{"bibtype":"article","type":"article","title":"Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study","volume":"28","issn":"1573-7241","shorttitle":"Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure","doi":"10.1007/s10557-013-6491-8","abstract":"PURPOSE: Over half of all admitted acute decompensated heart failure (ADHF) patients have renal failure. Although diuretics represent the mainstay of treatment strategy even in this population, there are unmet needs for safer and more effective treatment. Tolvaptan is a vasopressin-2 receptor antagonist, and we hypothesized that adding tolvaptan to standard diuretic therapy would be more effective in ADHF patients with renal function impairment. METHODS: The Answering question on tolvaptan's efficacy for patients with acute decompensated heart failure and renal failure (AQUAMARINE) is a multicenter, randomized controlled clinical trial, which will enroll 220 patients from 17 hospitals in Japan. ADHF patients whose estimated glomerular filtration rate is above 15 and below 60 mL/min/1.72 m(2) will be randomly assigned within 6 h after admission to usual care with furosemide or tolvaptan add-on therapy. Primary endpoint is achieved urine output within 48 h. Secondary endpoints include dyspnea relief measured by 7-points Likert scale, incidence of worsening renal function, dose of furosemide used within 48 h, and changes of brain natriuretic peptide. CONCLUSION: This study is the first multicenter study in Japan to evaluate clinical effectiveness of tolvaptan add-on therapy in ADHF patients with renal failure. The results of this study address the treatment strategy of this high-risk population (UMIN Clinical Trial Registry Number: UMIN000007109).","language":"eng","number":"1","journal":"Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy","author":[{"propositions":[],"lastnames":["Matsue"],"firstnames":["Yuya"],"suffixes":[]},{"propositions":[],"lastnames":["Suzuki"],"firstnames":["Makoto"],"suffixes":[]},{"propositions":[],"lastnames":["Nagahori"],"firstnames":["Wataru"],"suffixes":[]},{"propositions":[],"lastnames":["Yoshida"],"firstnames":["Kazuki"],"suffixes":[]},{"propositions":[],"lastnames":["Onishi"],"firstnames":["Yuko"],"suffixes":[]},{"propositions":[],"lastnames":["Satoh"],"firstnames":["Yasuhiro"],"suffixes":[]},{"propositions":[],"lastnames":["Ono"],"firstnames":["Yuichi"],"suffixes":[]},{"propositions":[],"lastnames":["Nishioka"],"firstnames":["Toshihiko"],"suffixes":[]},{"propositions":[],"lastnames":["Noda"],"firstnames":["Makoto"],"suffixes":[]},{"propositions":[],"lastnames":["Sugi"],"firstnames":["Kaoru"],"suffixes":[]},{"propositions":[],"lastnames":["Torii"],"firstnames":["Sho"],"suffixes":[]},{"propositions":[],"lastnames":["Tejima"],"firstnames":["Tamotsu"],"suffixes":[]},{"propositions":[],"lastnames":["Sakurada"],"firstnames":["Harumizu"],"suffixes":[]},{"propositions":[],"lastnames":["Yamaguchi"],"firstnames":["Satoshi"],"suffixes":[]},{"propositions":[],"lastnames":["Okishige"],"firstnames":["Kaoru"],"suffixes":[]},{"propositions":[],"lastnames":["Fujii"],"firstnames":["Hiroyuki"],"suffixes":[]},{"propositions":[],"lastnames":["Takahashi"],"firstnames":["Atsushi"],"suffixes":[]}],"month":"February","year":"2014","pmid":"24048511","keywords":"Acute Disease, Antidiuretic Hormone Receptor Antagonists, Benzazepines, Diuretics, Drug Therapy, Combination, Furosemide, Glomerular Filtration Rate, Heart failure, Humans, Japan, Natriuretic Peptide, Brain, Prospective Studies, Renal Insufficiency, Research Design","pages":"73--77","bibtex":"@article{matsue_clinical_2014,\n\ttitle = {Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the {AQUAMARINE} study},\n\tvolume = {28},\n\tissn = {1573-7241},\n\tshorttitle = {Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure},\n\tdoi = {10.1007/s10557-013-6491-8},\n\tabstract = {PURPOSE: Over half of all admitted acute decompensated heart failure (ADHF) patients have renal failure. Although diuretics represent the mainstay of treatment strategy even in this population, there are unmet needs for safer and more effective treatment. Tolvaptan is a vasopressin-2 receptor antagonist, and we hypothesized that adding tolvaptan to standard diuretic therapy would be more effective in ADHF patients with renal function impairment.\nMETHODS: The Answering question on tolvaptan's efficacy for patients with acute decompensated heart failure and renal failure (AQUAMARINE) is a multicenter, randomized controlled clinical trial, which will enroll 220 patients from 17 hospitals in Japan. ADHF patients whose estimated glomerular filtration rate is above 15 and below 60 mL/min/1.72 m(2) will be randomly assigned within 6 h after admission to usual care with furosemide or tolvaptan add-on therapy. Primary endpoint is achieved urine output within 48 h. Secondary endpoints include dyspnea relief measured by 7-points Likert scale, incidence of worsening renal function, dose of furosemide used within 48 h, and changes of brain natriuretic peptide.\nCONCLUSION: This study is the first multicenter study in Japan to evaluate clinical effectiveness of tolvaptan add-on therapy in ADHF patients with renal failure. The results of this study address the treatment strategy of this high-risk population (UMIN Clinical Trial Registry Number: UMIN000007109).},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy},\n\tauthor = {Matsue, Yuya and Suzuki, Makoto and Nagahori, Wataru and Yoshida, Kazuki and Onishi, Yuko and Satoh, Yasuhiro and Ono, Yuichi and Nishioka, Toshihiko and Noda, Makoto and Sugi, Kaoru and Torii, Sho and Tejima, Tamotsu and Sakurada, Harumizu and Yamaguchi, Satoshi and Okishige, Kaoru and Fujii, Hiroyuki and Takahashi, Atsushi},\n\tmonth = feb,\n\tyear = {2014},\n\tpmid = {24048511},\n\tkeywords = {Acute Disease, Antidiuretic Hormone Receptor Antagonists, Benzazepines, Diuretics, Drug Therapy, Combination, Furosemide, Glomerular Filtration Rate, Heart failure, Humans, Japan, Natriuretic Peptide, Brain, Prospective Studies, Renal Insufficiency, Research Design},\n\tpages = {73--77}\n}\n\n","author_short":["Matsue, Y.","Suzuki, M.","Nagahori, W.","Yoshida, K.","Onishi, Y.","Satoh, Y.","Ono, Y.","Nishioka, T.","Noda, M.","Sugi, K.","Torii, S.","Tejima, T.","Sakurada, H.","Yamaguchi, S.","Okishige, K.","Fujii, H.","Takahashi, A."],"key":"matsue_clinical_2014","id":"matsue_clinical_2014","bibbaseid":"matsue-suzuki-nagahori-yoshida-onishi-satoh-ono-nishioka-etal-clinicaleffectivenessoftolvaptaninpatientswithacutedecompensatedheartfailureandrenalfailuredesignandrationaleoftheaquamarinestudy-2014","role":"author","urls":{},"keyword":["Acute Disease","Antidiuretic Hormone Receptor Antagonists","Benzazepines","Diuretics","Drug Therapy","Combination","Furosemide","Glomerular Filtration Rate","Heart failure","Humans","Japan","Natriuretic Peptide","Brain","Prospective Studies","Renal Insufficiency","Research Design"],"downloads":0},"search_terms":["clinical","effectiveness","tolvaptan","patients","acute","decompensated","heart","failure","renal","failure","design","rationale","aquamarine","study","matsue","suzuki","nagahori","yoshida","onishi","satoh","ono","nishioka","noda","sugi","torii","tejima","sakurada","yamaguchi","okishige","fujii","takahashi"],"keywords":["acute disease","antidiuretic hormone receptor antagonists","benzazepines","diuretics","drug therapy","combination","furosemide","glomerular filtration rate","heart failure","humans","japan","natriuretic peptide","brain","prospective studies","renal insufficiency","research design"],"authorIDs":[],"dataSources":["TML33E22xSRKFfezh"]}